Endometrial Cancer Trial, Recruiting NCT05761561 Sponsor: Yale University Condition: Endometrial Cancer
Back to Endometrial Cancer

Endometrial Cancer Trial, Recruiting

NCT05761561
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal carcinoma (any stage), OR advanced or spreading endometrial cancer (including carcinosarcoma), AND whose treatment plan includes the chemotherapy drugs carboplatin and taxane (or a similar combination)
  • People who are scheduled to receive at least 6 rounds of chemotherapy before or after surgery
  • People who are able to walk on their own without a cane, walker, or other walking aid
  • People who are able to fill out forms, follow instructions, and read materials written in English or Spanish
  • People who are willing to be randomly assigned to one of two groups in the study
  • People whose cancer specialist has given approval for them to take part
  • People who are 18 years of age or older

Who may not be able to join:

  • People who have already finished their second round of chemotherapy
  • People who, since their diagnosis, have already been eating more than 7 servings of fruit and vegetables per day, OR doing at least 150 minutes per week of moderate to vigorous exercise along with strength training twice a week
  • People who are pregnant or planning to become pregnant
  • People who have had a stroke, heart attack, or heart failure (or have a weakened heart pumping less than 40% of normal capacity) within the past year
  • People who have dementia or a major psychiatric condition
  • People currently receiving targeted therapy or biological therapy for any other cancer (hormone therapy is not included in this restriction)
  • People currently receiving external beam radiation therapy

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Registry
ClinicalTrials.gov
Start date
19 April 2023
Est. completion
1 June 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Chemotherapy completion rate (relative dose intensity)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov